The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer

被引：0
|
作者：
Theodora A. Constantin
Anabel Varela-Carver
Kyle K. Greenland
Gilberto Serrano de Almeida
Ellen Olden
Lucy Penfold
Simon Ang
Alice Ormrod
Damien A. Leach
Chun-Fui Lai
Edward K. Ainscow
Ash K. Bahl
David Carling
Matthew J. Fuchter
Simak Ali
Charlotte L. Bevan
机构：
[1] Imperial College London,Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer
[2] Hammersmith Hospital,MRC London Institute of Medical Sciences, Imperial College London
[3] Carrick Therapeutics,Department of Chemistry, Molecular Sciences Research Hub
[4] Nova UCD,undefined
[5] Bellfield Innovation Park,undefined
[6] Imperial College London,undefined
来源：
British Journal of Cancer | 2023年 / 128卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2326 / 2337
页数：11
相关论文
共 19 条
  • [1] The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
    Constantin, Theodora A.
    Varela-Carver, Anabel
    Greenland, Kyle K.
    de Almeida, Gilberto Serrano
    Olden, Ellen
    Penfold, Lucy
    Ang, Simon
    Ormrod, Alice
    Leach, Damien A.
    Lai, Chun-Fui
    Ainscow, Edward K.
    Bahl, Ash K.
    Carling, David
    Fuchter, Matthew J.
    Ali, Simak
    Bevan, Charlotte L.
    BRITISH JOURNAL OF CANCER, 2023, 128 (12) : 2326 - 2337
  • [2] The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer (vol 128, pg 2326, 2023)
    Constantin, Theodora A.
    Varela-Carver, Anabel
    Greenland, Kyle K.
    de Almeida, Gilberto Serrano
    Olden, Ellen
    Penfold, Lucy
    Ang, Simon
    Ormrod, Alice
    Leach, Damien A.
    Lai, Chun-Fui
    Ainscow, Edward K.
    Bahl, Ash K.
    Carling, David
    Fuchter, Matthew J.
    Ali, Simak
    Bevan, Charlotte L.
    BRITISH JOURNAL OF CANCER, 2024, 130 (05) : 892 - 892
  • [3] A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
    Howell, Sacha J.
    Kenny, Laura M.
    Lord, Simon
    Krebs, Matthew G.
    Arkenau, Tobias
    Baird, Richard
    MacPherson, Iain R.
    Bahl, Ash
    Clack, Glen
    Ainscow, Edward
    Barrett, Anthony G. M.
    Dickinson, Paul A.
    Fuchter, Matthew J.
    Lehnert, Manfred
    Ali, Simak
    McIntosh, Stuart
    Coombes, Charles
    CANCER RESEARCH, 2022, 82 (04)
  • [4] First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies
    Krebs, M. G.
    Lord, S.
    Kenny, L.
    Baird, R. D.
    MacPherson, I.
    Bahl, A.
    Clack, G.
    Ainscow, E.
    Barrett, A. G.
    Dickinson, P.
    Fuchter, M. J.
    Lehnert, M.
    Ali, S.
    Mcintosh, S.
    Coombes, R. C.
    ANNALS OF ONCOLOGY, 2021, 32 : S458 - S458
  • [5] Defining modulators of response to samuraciclib, a CDK7 inhibitor for breast cancer
    Jurgaityte, Kaste
    Sava, Georgina
    Lai, Chun Fui
    Fan, Hailing
    Nguyen, Van
    Buluwela, Laki
    Ali, Simak
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR plus BC)
    Coombes, Charles
    Howell, Sasha J.
    Krebs, Matthew G.
    Lord, Simon
    Kenny, Laura M.
    Bahl, Ash
    Clack, Glen
    Ainscow, Edward
    Dickinson, Paul A.
    Fostea, Raluca
    Mansi, Janine
    Palmieri, Carlo
    Bertelli, Gianflippo
    Jeselsohn, Rinath
    Mitri, Zahi
    Gradishar, William J.
    Sardesai, Sagar
    O'Shaughnessy, Joyce
    Ward, Patrick
    Chalasani, Pavani
    Lehnert, Manfred
    Ali, Simak
    McIntosh, Stuart
    CANCER RESEARCH, 2022, 82 (04)
  • [7] Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR plus BC)
    Howell, S. J.
    Krebs, M. G.
    Lord, S.
    Kenny, L.
    Bahl, A.
    Clack, G.
    Ainscow, E.
    Arkenau, H-T.
    Mansi, J. L.
    Palmieri, C.
    Richards, P.
    Jeselsohn, R.
    Mitri, Z.
    Gradishar, W. J.
    Sardesai, S.
    O'Shaughnessy, J.
    Lehnert, M.
    Ali, S.
    McIntosh, S.
    Coombes, R. C.
    ANNALS OF ONCOLOGY, 2021, 32 : S477 - S478
  • [8] CT7001: An orally bioavailable CDK7 inhibitor is a potential therapy for breast, small-cell lung and haematological cancers
    Ainscow, Edward K.
    Leishman, Andrew
    Sullivan, Elaine
    Li, Bo
    Gallagher, William
    Peall, Adam
    Clark, Kristopher
    Thomson, Stuart
    Ali, Simak
    Coombes, Raoul C.
    Bahl, Ash
    CANCER RESEARCH, 2018, 78 (13)
  • [9] CT7001, a Novel Orally Bio-Available CDK7 Inhibitor, Is Highly Active in in-Vitro and in-Vivo Models of AML
    Clark, Kristopher
    Ainscow, Edward
    Peall, Adam
    Thomson, Stuart
    Leishman, Andrew
    Elaine, Sullivan
    Ali, Simak
    Coombes, Raoul
    Barrett, Anthony
    Bahl, Ash Kumar
    BLOOD, 2017, 130
  • [10] The covalent CDK7 inhibitor THZ1 targets super-enhancer associated oncogenes in bladder cancer
    Yang, Yafei
    Pang, Jun
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 106 - 107
12